.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very strange... Maybe a sign of what's to come tomorrow? ;)
jmo.
GLTA.
Potential BioShocker -- NVLT.OB
BMR Article -- http://biomedreports.com/component/content/article/56-top-leading-news/22199-novelos-eyeing-qrevolutionaryq-phase-iii-cancer-study-results.html
Do your OWN DD before investing.
GLTA.
Yeah. Down over 50% from their highs in September... IMO it is a great buy anywhere under $1, may return to $2+ in the next month or two!
JMO.
GLTA.
In case you missed the webcast Tuesday...
It can be replayed here: http://www.informedinvestors.com/IIF/IIF_Client.asp?clientID=44356
GLTA.
IMO if that happens, it'll be mid-2010...
JMO.
GLTA.
do your own dd before investing.
Just found out about this stock from BMR... Looks good, imo.
GLTA.
From the website:
In Russia
Numerous clinical studies have been concluded in Russia over the last decade, and NOV-002 was approved as an adjunct to chemotherapy in the Russian Federation in 1998. The Russian approval was obtained by demonstrating clinical efficacy and excellent safety in 340 patients with many types of cancers, including: lung, colorectal, breast, ovarian, pancreatic, etc.
Overall, the studies revealed that NOV-002 could be safely and effectively added to various chemotherapy regimens. The treated patients had a better quality of life and more rapid restoration of hematological and immunological indices. They tolerated the combination therapy better than standard chemotherapy alone, as evidenced by receiving greater number of chemotherapy cycles. Further, in a controlled Russian lung cancer trial, when used in combination with chemotherapy, NOV-002 increased the one year survival rate of patients from 17% to 63% (p < 0.01), a result that represents an 80% improvement over the 35% survival rate seen with the current standard of care in the U.S.
NOV-002 also sensitized previously platinum-resistant ovarian cancer patients to chemotherapy in a Russian-based trial. In combination with NOV-002, 80% of the treated women responded favorably to the same chemotherapy that they previously failed.
Novelos' CEO Eyeing "Revolutionary" Phase III Results
Written by M.E.Garza
Wednesday, 16 December 2009 00:00
"What's interesting about Novelos is that we're in a Pivotal Phase III trial for lung cancer under both SPA and Fast Track for our NOV-002 lead compound," explains Novelos Therapeutics' (OTC: NVLT) Chief Executive Officer, Harry S. Palmin.
The study, a randomized, open-label, Phase 3 Trial of NOV-002 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin alone for the treatment of advanced non-small cell lung cancer is being conducted under the FDA's Special Protocol Assessment. It blinds Novelos from seeing any results as it progresses.
In other words, there is no interim analysis. There is only "one look" and that look occurs once 725 deaths take place during the trial.
"These patients with a median survival of eight to ten months unfortunately die pretty quickly," explains Novelos Therapeutics' Chief Executive Officer, Harry S. Palmin. "One year survival, which is another way to look at this, is just about 40%."
Quick Fact:
Purdue Pharma (of OxyContin® fame) is making a concerted push in cancer treatments and recently completed a $9M private placement in NVLT in exchange for the exclusive rights to negotiate for the US opportunity to NOV-002 through the end of Phase III. Mundipharma AG has the NOV-002 rights in EUR & Asia (ex-China).
The pivotal study itself began more than three years ago, in November of 2006. By March of 2008, the enrollment target of patients had been reached and now, over a year and a half later, the 725th event has not yet occurred.
It's become pretty obvious, even to the most casual observer, that the patients involved in the trial are living longer than expected and that, in fact, is one of the reasons why Wall Street has begun to take more interest in the company and the study. Originally, most observers, including insiders at the company, expected that the trial might reach a conclusion some time during the middle of this year.
"It's a very unique value proposition," says Palmin. "If you think of Avastin, Roche's drug, it's the only drug in non-small cell lung cancer, first line treatment that showed a survival advantage. They showed a two month survival advantage, 12.3 months versus 10.3, but the drug has severe toxicities associated with it on top of the chemotherapy toxicities and it's very expensive. It's also only available to very few lung cancer patients because the histology it works for is non-squamous.
"The point that I'm trying to make is that given our current statistical projections, because our trial is going late, if we assume that the control group does in fact what it's supposed to, around a ten month median survival, and there's historical data on some four-thousand patients with advanced stage lung cancer that have taken our type of chemotherapy (paclitaxel/carboplatin [standard of care in the U.S.]), then we should be on track to achieve or possibly even exceed our possible twelve and a half month median survival target.
"By way of background, we started the pivotal Phase III on lung cancer on the back of three Phase II's," explains Palmin. "Same patient population and in two of the trials that were done in Russia, we saw dramatic survival advantages, better anti-tumor effects and in the United States, we saw doubling response rates and better toleration of chemotherapy. So there are three lung cancer trials that were the basis for the pivotal Phase III. We, of course, have applicability to other indications because we're not tumor specific and we're not chemotherapy specific."
That is an important point that has not gone unnoticed. This year, Perdue Pharma has invested over $19 million dollars in Novelos. The company itself, since going public over 5 years ago, has raised over $70 million dollars.
"We had good data out of Russia in non-small cell lung and it is the number one cancer killer, currently; late stage lung cancer," says Palmin. "There are north of two-hundred thousand new patients each year and more than one hundred and sixty thousand deaths and it's a huge market. Just lung cancer is north of a $3.5 billion dollar market.
"Since we have applicability, really, to all solid tumors, in Russia the drug is already approved for general use with chemotherapy. Here in the United States, we've had two positive Phase II results in ovarian and breast cancer. Channel 7 in Miami recently profiled a breast cancer patient that was in our Phase II breast cancer trial and went into complete remission. No signs of cancer. That's based on publicly available information where we've had forty percent of the patients have had no sign of their cancer after treatment of chemo and our drug.
"In addition, the patients that take our drug with the chemotherapy have a much better quality of life while under that treatment, versus being on chemo alone. Plus, very importantly, there is the efficacy improvement. That makes this a very different approach to the treatment of cancer."
BioMedReports: Can you tell us about the mechanism of the drug?
Palmin: "In short, what we do is we regulate redox-sensitive cell signaling pathways that are involved in cancer proliferation, cell-mediated immunity and blood recovery, basically. Recovery from chemotherapy toxicity.
"Some companies tried to use oxidative stress as a way to kill tumors and not surprisingly, that can result in pretty severe side effects for the patient. What we do, is we administer our proprietary formulation of Oxidized glutathione (NOV-002), which induces transient oxidative signal throughout the body and that has pretty profound, different effects in tumor cells versus normal cells. So what we've seen- and this is in patients, in vivo (experimentation using a whole, living organism as opposed to a partial or dead organism), in animals and in vitro experiments (performed not in a living organism but in a controlled environment, such as in a test tube), what we've seen is this different effect on tumor versus normal cells.
"So in tumor cells, we actually potentiate the chemotherapy. We make the cancer cells more sensitive to chemotherapy and we also inhibit the cancer's ability to metastasize (spread). so there are all sorts of interesting effects that happen at the tumor level. However, on the normal cells- for example bone marrow cells and blood cells- which of course get damaged by chemotherapy, we don't stop the damage but we do help the recovery from that damage. In the words of big pharma, 'if this Phase III trial is positive, this will be revolutionary for the cancer field.'
"We're well funded. We are expecting this Pivotal Phase III outcome in early 2010. We have about a year's worth of funding, so the plan is that as soon as the data is out, we're going to work with a bulge investment bank - like are you familiar with the Dendreon story?
BioMedReports: Of course.
Palmin: "The idea is to do something very similar as soon as our data is out. So they were a four or five dollar stock that had a positive Phase III in prostate cancer under a similar SPA and Fast Track and, of course, they jumped to a several billion market cap.
BioMedReports: What are you trading at now?
Palmin: "We're trading at around a dollar, we have 117 million shares outstanding (40 million in the float) between common and preferred, which puts us at about $100 million market cap.
"Cougar (Biotechnology) was purchased by Johnson and Johnson for $1 billion in May and that was short of their Phase III results. Our shares at $6 puts us at $1 billion market cap, so our feeling is, that if this Phase III is positive- and there are a lot of reasons to be encouraged even though there are no guarantees- things will play out nicely.
BioMedReports: This sounds like a winner.
Palmin: "I couldn't agree more. Over the past two and a half years I've bought four hundred thousand shares at market.
"There's actually pretty ample liquidity and there's been a fair amount of trading.
"Elemer Piros of Rodman & Ranshaw has covered us with a $3 price target and Raymond Myers, at Emerging Growth Equities has a $5 price target. Our challenge has been to get more coverage on Wall Street and once the Phase III data comes in, of course, that won't be a problem. We already know bulge banks that would want to initiate on us. We do not pay for research. No fees in terms of stock or cash. Even the attention we've gotten thus far has been unsolicited.
"The current approach is to spread the word as much as possible, to get more eyeballs on us so that when the data comes out, to the extent that as people get focused on us earlier, then all the better of course."
Biotech investors know that anything can happen in a single Phase II result. Whats nice about Novelos' situation is that they've had no bad news and lots of positive news.
In their lung cancer studies alone they've had three positive Phase II studies- all prior to starting this large 900 patient Phase III trial.
In other indications, in the U.S., the company announced positive results in breast cancer and ovarian cancer and it's nice to have the validation from Russia across many thousands of patients.
BioMedReports: What are your plans for bringing the drug to market yourself?
Palmin: "I would say that we have a competitive advantage on the clinical and development side and that we have a disadvantage when it comes to on the marketing.
"In the United States, our plan is that as soon as the Phase III data is out for us to hold a competitive auction for the U.S. Rights."
Developing...
Disclosure: long NVLT
ANX forming higher lows... Looks better than ever, imo.
NDA filing within a month, according to CEO. Also, they have enough cash to last them through FDA decision (was in one of their PRs).
I highly suggest listening to the webcast from the Lippert/Heilshorn Conference. Tells you a lot about the company.
GLTA.
Disclaimer: Do your own DD before investing.
Yeah. Definitely.
IMO, 2010 will be a stellar year for ACTC -- IND approval, etc...
GLTA.
ACTC looks a whole lot better now than it did earlier this year; it's out of the pinks and on the bulletin board.
I'll keep an eye on it, thanks for the postt!
GLTA.
Welcome!
Here's a helpful post from the Yahoo! Message Boards:
Reaffirmed NDA for ANX-530 in 2009.
Discussed FDA meeting for ANX-514 NDA in nex30 days.
Touched upon $3 billion market for ANX-514.
Reaffirmed Korean pharma partner, Shin Poong.
Discussed business structure and nonemulsion technology, which has little overhead.
Reported that the company has 12 months worth of CASH ON HAND.
Link: http://messages.finance.yahoo.com/Stocks_(A_to_Z)/Stocks_A/threadview?m=tm&bn=1150&tid=52429&mid=52429&tof=1&frt=2
GLTY.
We're forming higher lows! I believe yesterday's low was .123, today's is .13!
jmo.
GLTA.
Do your own DD before investing.
Probably profit takers getting out...
JMO.
GLTY.
Going to jump back in tomorrow...
GLTA.
I think the float is around 149M.
I believe this was the last financing deal: http://finance.yahoo.com/news/ADVENTRX-Pharmaceuticals-prnews-1895569356.html?x=0&.v=1
If you have any more questions let me know.
GLTA!
Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease
Two Highest Doses Removed from Phase II Trial, Lowest Dose Continues as Planned
* Press Release
* Source: Elan Corporation, plc and Transition Therapeutics, Inc.
DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease. The AD201 study is evaluating three dose levels of ELND005 compared to placebo in 353 patients.
Patients will be withdrawn immediately from the study in the two higher dose groups (1000mg and 2000mg dosed twice daily). The study will continue unchanged for patients who are assigned to the lower dose (250mg dosed twice daily) and placebo groups. The AD251 study will be modified to dose patients only at 250mg twice daily.
The decision by the companies to take these actions was made in concurrence with the Independent Safety Monitoring Committee (ISMC) following a review of the ongoing ELND005-AD201 study. Greater rates of serious adverse events, including nine deaths, were observed among patients receiving the two highest doses. A direct relationship between ELND005 and these deaths has not been established.
The ISMC and both companies concur that the tolerability and safety data are acceptable among patients receiving the 250mg dose and that the blinded study should continue for this dose and the placebo group.
“Today’s decision speaks to our strong commitment to patient safety while allowing for the continued evaluation of ELND005 at the 250mg dose, twice daily,” said Menghis Bairu, M.D., EVP, Chief Medical Officer and Head of Global Development at Elan. “We continue to expect the ongoing study to provide important data to guide the next steps in the development of ELND005 for the potential treatment Alzheimer’s disease.”
About ELND005 (AZD-103)
ELND005 is an orally-administered therapeutic agent that has received fast track designation from the U.S. Food and Drug Administration (FDA) for treatment of mild to moderate Alzheimer's disease. Fast track designation can facilitate development and may expedite regulatory review of drugs that the FDA recognizes as potentially addressing an unmet medical need for serious or life-threatening conditions.
ELND005 is currently in a Phase 2 clinical study, which completed enrollment in October 2008. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in approximately 353 patients with mild to moderate Alzheimer's disease. The planned treatment period for each patient is approximately 18 months.
About Alzheimer's disease
Alzheimer's disease, a leading cause of dementia, is a progressive brain disorder that gradually destroys a person's memory and ability to learn reason, make judgments, communicate and carry out daily activities. Alzheimer's disease may result from the build-up of toxic beta-amyloid peptides in the brain. As Alzheimer's disease progresses, individuals may also experience changes in personality and behavior, such as anxiety, suspiciousness or agitation, as well as delusions or hallucinations. It is currently estimated that more than 5 million Americans have Alzheimer's disease and more than 24 million people worldwide over the age of 60 have some form of dementia (Source: Alzheimer's Association and Alzheimer's Disease International).
About Elan
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
About Transition
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT-223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the Company, please visit www.transitiontherapeutics.com.
Safe Harbor/Forward-Looking Statements
This press release contains forward-looking statements regarding the development of scyllo-inositol (ELND005) under the collaboration agreement between Elan and Transition. These statements are based on Elan's and Transition's current beliefs and expectations. ELND005 may not be successfully developed or commercialized under the collaboration agreement. Factors which could cause actual results to differ materially from Elan's and Transition's current expectations include the risks that clinical development of ELND005 fails due to safety or efficacy issues, the results from Phase 1 clinical trials and preclinical testing of ELND005 are not predictive of results to be obtained in Phase 2 or later clinical trials, the patent issued with respect to ELND005 may not provide substantial protection or commercial benefit, the development and commercialization of competitive therapies, the collaboration agreement is terminated early or Elan and Transition encounter other unexpected delays or hurdles. Drug development and commercialization involves a high degree of risk.
For more detailed information on the risks and uncertainties associated with Elan and Transition's drug development and other activities, see the periodic and current reports that Elan has filed with the Securities and Exchange Commission and that Transition has filed with the Securities and Exchange Commission and the Ontario Securities Commission. Elan and Transition assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6120846<=en
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6120846
Roth Capital downgrades TTHI to Hold from Buy and lowers their tgt to $6 from $13. The firm notes TTHI's ELN005 is currently in a Phase 2 clinical study to treat Alzheimer's. However, after meeting with the Independent Safety Monitoring Committee the firm announced thsi morning that it was discontinuing dosing at the 2 highest dose levels of this study, 1 and 2 g. This decision was made based on an excess of serious adverse events in these treatment group, including 9 deaths. There was also a death in either the low dose or placebo group. The first Phase 1 studies did not demonstrate any toxicity, though the doses in this study were not disclosed. While ELND005 may still be a viable drug, and the firm hopes that it succeeds, the imbalance in deaths and potential that the current Phase 2 study may not be able to afford a statistically significant result is a great concern. Based on today's data, the firm now thinks that odds of ELND005 reaching the market in 2014 are 15% down from 25%.
NDA to be filed within a month for ANX-530... Pre-NDA meeting sometime in 2010 for ANX-514. Overall very positive. IMHO it's profit takers taking us down...
jmo.
GLTA.
Here's the link to the ADVENTRX Pharmaceuticals, Inc. (ANX) webcast @ the Lippert/Heilshorn Life Sciences Conference: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=153266
GLTA.
The audio webcast went very well, in my opinion... Very promising.
jmo
GLTA.
Chelsea Therapeutics Granted Approval to Change the Primary Endpoint and Increase Enrollment in Droxidopa Pivotal Study 301
* Press Release
* Source: Chelsea Therapeutics
* On 8:30 am EST, Tuesday December 15, 2009
Top-line Data Expected in Third Quarter 2010
Chelsea Management to Host Conference Call Today at 10:00 AM EST
CHARLOTTE, N.C., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP - News) announces that the FDA has agreed to allow the company to modify the primary endpoint and enroll an additional 24 patients in Study 301, a pivotal Phase III study of Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).
The primary endpoint of the trial will now be the relative mean change in the Orthostatic Hypotension Questionnaire (OHQ) composite score between Droxidopa and placebo. The OHQ composite score is a single endpoint that reflects the average of the composite orthostatic hypotension symptom assessment (OHSA) score and the composite orthostatic hypotension daily activities scale (OHDAS) score. The FDA agreed that the revised primary endpoint reflects a more comprehensive global assessment of the clinical benefit of Droxidopa for the treatment of symptomatic NOH in primary autonomic failure, a heterogeneous population consisting of patients suffering from Parkinson's Disease (PD), multiple system atrophy (MSA) and pure autonomic failure (PAF) and would therefore be suitable for supporting a symptomatic claim.
To further de-risk the study and maximize the potential significance of the outcome, Chelsea has decided to increase the power of the study to greater than 80% by randomizing an additional 24 patients into Study 301. The company plans to reopen enrollment at select North American centers. Based on discussions with study investigators, historical rates of recruitment and the total patient requirement, Chelsea anticipates that Study 301 will complete enrollment by the end of the second quarter 2010, allowing for top-line study data in the third quarter of 2010.
The FDA confirmed that while Study 302, which failed to achieve statistical significance using only item 1 of the OHSA as a primary endpoint, and so could not be used as a pivotal study, it did provide valuable information about the benefits of Droxidopa. Both the safety and efficacy data from this study will be considered to be a supportive part of future regulatory filings. Further, the agency indicated that the number of patients already enrolled in Chelsea's pivotal program would be sufficient to support an NDA in this indication.
The FDA has, however, also recommended that Chelsea submit a confirmatory study to support an NDA filing. The FDA indicated that such a study could be contained to a small, highly enriched, homogeneous patient population. The FDA also suggested Chelsea utilize an innovative design with the option to include multiple crossovers, wherein each patient serves as his or her own control, minimizing individual patient variability.
Based on these recommendations, Chelsea will to initiate a new clinical trial, Study 306, early in 2010. While final study protocols are still being finalized, the company anticipates that a prospective study would seek to evaluate the efficacy of Droxidopa in approximately 35-45 PD patients with symptomatic NOH using the OHQ score as the primary endpoint. The company anticipates that a trial of this scope could be completed by the end of 2010, allowing for an NDA filing in early 2011.
"The results of Study 302, our first Phase III study of Droxidopa in NOH, provided a wealth of useful data supporting the clinical efficacy of Droxidopa and the utility of the OHQ as a comprehensive measure of disease activity," commented Dr. Simon Pedder, President and CEO of Chelsea Therapeutics. "Modifying the primary endpoint to the more global OHQ composite score substantially increases the likelihood that Study 301 will capture the full therapeutic benefit of Droxidopa in symptomatic NOH. Based on the results from Study 302, particularly our recent subgroup analysis of PD patients, we are confident that we can achieve a statistically significant outcome to support our NDA filing in a smaller confirmatory study in PD patients."
Conference Call Today at 10:00 AM EST
Chelsea will discuss the changes to its Droxidopa registration program in NOH today, December 15, 2009, at 10:00 AM Eastern Time. Interested investors may participate in the conference call by dialing (866) 818-1395 (domestic) or (703) 639-1379 (international). A replay will be available for one week following the call by dialing 888-266-2081for domestic participants or 703-925-2533for international participants and entering passcode 1421550 when prompted. Participants may also access both the live and archived webcast of the conference call on Chelsea's web site at www.chelseatherapeutics.com.
About Droxidopa
Droxidopa, the lead investigational agent in Chelsea Therapeutics' broad pipeline, is currently in Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure - a group of diseases that includes Parkinson's disease, multiple systems atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally. Droxidopa is also being studied for the treatment of fibromyalgia in an ongoing phase II trial and completed a phase II trial in intradialytic hypotension (IDH) study with positive results.
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include our need to raise operating capital, our history of losses, risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates Droxidopa and CH-1504, reliance on collaborations and licenses, intellectual property risks, competition, market acceptance for our products if any are approved for marketing and reliance on key personnel including specifically Dr. Pedder.
NEXM @ 0.50 Pre-Market!
GLTA.
Yeah, DSCO looks great at these levels.
Thanks for the compliments & GLTY!
.50x.52 PM.
GLTA.
Good morning!
Great news for NEXM, imo. Looks like it's going to rock today!
Thanks for posting!
jmo
GLTA.
Hopefully the board will start to pick up some traffic soon. :)
I've been keeping an eye on ANX since the summer. Really, there's no way to tell if they're going to announce NDA submission in the presentation. If they do, it could be big, but if they don't, it will most likely imo go back down.
Really its just whatever you feel most comfortable doing.
Thanks for stopping by!
GLTY.
Nope. But some of us are speculating it'll include them giving a date for when the NDA will be filed, or else they'll announce that it has been filed.
GLTY.
HCEI L2 is pretty thin to $1!!
WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
GLTA.
Almost 5M volume in the first 30 minutes! Nice call!
GLTA.
Just got some BNVI, looks good, imo...
Do your OWN DD before investing.
GLTA.
Yeah! I'll take 50% any day! :)
GLTA.
Nice buy!
GLTA.
What's your target for BNVI?
GLTA.
Great! I'm going to try to snatch a few shares at market open.
GLTY.
Heh. I would already be rich but I sold out @ .5591! LOL.
GLTY>
Definitely considering taking a position in BNVI today.
GLTA.